ZVRA - Zevra Therapeutics, Inc.

Zevra Therapeutics is a specialty pharmaceutical company focused on rare and orphan diseases, with its primary commercial product being Miplyffa (arimoclomol), an FDA-approved oral capsule treatment for Niemann-Pick disease type C (NPC), a rare and fatal lysosomal storage disorder. The business model is specialty pharma direct-to-patient/physician with hospital and specialty pharmacy distribution, targeting a small population of NPC patients in the United States and pursuing European regulatory approval. Revenue is sub-$50M annually, heavily weighted toward the U.S. market, as Miplyffa received FDA approval in September 2024 and is in early commercial launch stages. The company also has AZSTARYS (serdexmethylphenidate/d-methylphenidate), a CNS stimulant for ADHD licensed to Corium, generating royalty revenue.

Past Year Trends

• ZVRA total revenue surged 351% year-over-year to $106.5 million in FY2025, driven almost entirely by the commercial launch of MIPLYFFA (arimoclomol), which generated $87.4 million in net revenue following its September 2024 FDA approval as the first-ever treatment for Niemann-Pick disease type C. (Bullish)
• Zevra sold a Rare Pediatric Disease Priority Review Voucher (PRV) in February 2025 for $150 million, a one-time cash windfall that helped flip the company from a net loss of $105.5 million in FY2024 to net income of $83.2 million in FY2025. (Bullish)
• MIPLYFFA quarterly net revenue accelerated sequentially from $22.4 million in Q3 2025 to $26.4 million in Q4 2025, a 18% quarter-over-quarter increase, reflecting continued patient uptake in the ultra-rare NPC patient population. (Bullish)

Next Year Trends

• MIPLYFFA growth is constrained by the extremely small NPC patient population (estimated 500–1,000 diagnosed patients in the U.S.), and with early commercial penetration already captured, revenue upside from new patient additions may decelerate materially in the next 12 months. (Bearish)
• OLPRUVA (sodium phenylbutyrate) net revenue remained minimal at $0.8 million for full-year 2025, and its commercial trajectory relative to existing urea cycle disorder competitors will be a key test of Zevra's ability to diversify revenue beyond MIPLYFFA. (Neutral)
• Zevra enters 2026 with $238.9 million in cash and no near-term funded pipeline readouts disclosed, raising the question of whether management will deploy capital via an acquisition or in-licensing deal to sustain growth, which introduces execution risk if a transaction is pursued. (Neutral)

Red Flags

[Financial Restatement / Auditor Issue] The Audit Committee concluded that audited financial statements for FY2021 and FY2022 should no longer be relied upon due to improper accounting of common stock warrants as liabilities, with an estimated ~$14.8M impact to fair value adjustment income for FY2022, affecting multiple quarterly reports through September 2023. — SEC Form 8-K/A (Zevra Therapeutics Audit Committee disclosure), March 2024

[Financial Restatement / Auditor Issue] BDO USA, P.C. included an explanatory going concern paragraph in its audit report dated March 27, 2023, casting doubt on Zevra Therapeutics' ability to continue as a going concern. — BDO USA, P.C. audit report, March 2023

[Securities Fraud / Investigation] Multiple plaintiff law firms announced securities fraud investigations into Zevra Therapeutics on behalf of investors, triggered by the financial restatement disclosures. — Pomerantz LLP, Holzer & Holzer LLC, Kirby McInerney LLP (GlobeNewswire press releases), April 2024